> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ipsen sNDA for Somatuline Depot Approved
- URL: https://www.fdaweb.com/ipsen-snda-for-somatuline-depot-approved/
- Published: 2017-09-18T12:00:00.000Z
- Updated: 2026-09-14T22:50:56.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139650

FDA has approved an Ipsen Biopharmaceuticals supplemental NDA for Somatuline Depot (lanreotide) Injection 120 mg for treating carcinoid syndrome. The company says that when used for this indication, the therapy reduces the frequency of short-acting somatostatin analog rescue therapy. Somatuline Depot is also approved for improving progression-free survival in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.